2144 NEW ZEALAND GAZETTE, No. 78 20 JUNE 2013

Product: Ritalin LA
Active Ingredient: Methylphenidate hydrochloride 30mg
Dosage Form: Modified release capsule
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Alkermes Gainesville LLC, Georgia, United States of America

Product: Ritalin LA
Active Ingredient: Methylphenidate hydrochloride 40mg
Dosage Form: Modified release capsule
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Alkermes Gainesville LLC, Georgia, United States of America

Product: Ritalin LA
Active Ingredient: Methylphenidate hydrochloride 10mg
Dosage Form: Modified release capsule
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Alkermes Gainesville LLC, Georgia, United States of America

Product: Ritalin SR
Active Ingredient: Methylphenidate hydrochloride 20mg
Dosage Form: Modified release tablet
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Patheon Inc, Ontario, Canada

Dated this 13th day of June 2013.

DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health
(pursuant to delegation given by the Minister of Health on 6 July 2001).

go3730

Justice

Anti-Money Laundering and Countering Financing of Terrorism Act 2009

Ministerial Exemptions under the Anti-Money Laundering and Countering Financing of Terrorism Act 2009

In accordance with section 159(3) of the Anti-Money Laundering and Countering Financing of Terrorism Act 2009 (“AML/CFT Act”), the Minister of Justice hereby gives notice that she has granted the following exemptions from the AML/CFT Act:

Ministerial Exemption: Government Superannuation Fund Authority

1. As the Minister of Justice and pursuant to section 157 of the AML/CFT Act, I partially exempt the Government Superannuation Fund Authority (“Authority”) from Part 2 of the AML/CFT Act in relation to its role as administrator and manager of the Government Superannuation Fund (“Fund”).

2. This exemption is made subject to the following conditions:

(a) The Authority is required to comply with subpart 2 of Part 2 of the AML/CFT Act in relation to suspicious transaction reports.

(b) The Authority must undertake enhanced customer due diligence on every member applying to purchase service.

(c) The Authority is required to comply with section 26 of the AML/CFT Act and take reasonable steps to determine whether any of its existing members are politically exposed persons (PEPs). Reasonable steps should be taken to trace the source of funds if any PEPs identified attempt to purchase service or introduce other funds separate from payroll.

(d) The Authority is required to prepare a risk assessment in line with the requirements of section 58 of the AML/CFT Act.

(e) The Authority is required to undertake a comprehensive review of its risk assessment if there is a material change to its business or the operation of any of the superannuation schemes which make up the Fund.

(f) If, following a review, the Authority considers that it faces a materially greater ML/FT risk as a result of that change, it is required to notify the Ministry and FMA and undertake to work with those bodies to agree how to manage that risk.

(g) The Authority must appoint an Anti-Money Laundering and Countering Financing of Terrorism compliance officer to oversee compliance with these conditions.

3. This exemption will come into force on 30 June 2013.

4. This exemption will expire on 30 June 2018.

Ministerial Exemption: Funeral Directors Association of New Zealand

1. As the Minister of Justice and pursuant to section 157 of the AML/CFT Act, I partially exempt the Funeral Directors Association of New Zealand (FDANZ) from Part 2 of the AML/CFT Act in relation to its role as trustee of the FDANZ Funeral Trust.

2. This exemption is made subject to the following conditions:

(a) Enhanced customer due diligence (CDD) in accordance with the AML/CFT Act is required on account balances that have accumulated an amount over the threshold value of $29,999.99.

(b) Suspicious transaction reports are to be carried out in accordance with subpart 2 of Part 2 of the AML/CFT Act.